Artificial Intelligence

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

Otis secures a major TfL contract to upgrade 172 escalators, blending a century of history with future-ready tech for a smarter, more reliable commute.

A looming 10-million-ton copper deficit threatens to derail the AI revolution and the green energy transition, sparking a new era of geopolitical competition.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

CN Energy's robotics arm, Pathenbot, just won a key "Investment-Ready" award at CES 2026. What does this reveal about its disruptive tech and global plans?

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.

As the eVTOL race intensifies, Vertical Aerospace appoints key execs from Lotus, Nike, and AB InBev to spearhead its push for certification and scale.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

A $10 billion fund. Two competing visions. Wingspan Advisors' unique 'Alpha Summit' will decide the future of its ambitious new investment vehicle.

A landmark deal brings a leading U.S. venue management platform to Japan, South Korea, and Taiwan, aiming to transform fan safety and operations.

CEO Werner Lanthaler will present FairJourney Bio's data-driven antibody discovery platform at the elite J.P. Morgan conference, signaling major growth.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

The UK retail giant is ditching manual spreadsheets for an AI-driven platform to standardize labor and enhance customer experience across 240+ stores.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

A new clinical benchmark published in a Nature journal reveals a Chinese AI is the safest and most effective, challenging Silicon Valley's dominance.

At CES 2026, RobotEra's L7 humanoid and 'Hexa-Core' lineup showcase China's growing dominance in the global robotics race. Here's a deep dive.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Fresh off a CES 2026 Innovation Award win, ULS Robotics' new VIATRIX™ exoskeleton promises to bring industrial-strength assistance to everyday adventurers.

Beyond the hype, X-Humanoid's robots are running marathons and working on production lines, signaling a major shift from lab demos to real-world deployment.